Company Filing History:
1 out of 5,207 
1 out of 3,378 
1 out of 832,812 Years Active: 1992-2009
Title: The Innovative Contributions of Robert Zand
Introduction
Robert Zand is a notable inventor based in Ann Arbor, MI (US). He has made significant contributions to the field of technology and medicine, holding 2 patents that showcase his innovative spirit and dedication to advancing scientific knowledge.
Latest Patents
Zand's latest patents include groundbreaking work in radiosensitizer formulations and methods for use. This invention provides radiosensitizer compositions in controlled-release formulations, particularly nitrohistidine radiosensitizer compositions. These compositions can be administered through various means, including oral, intravenous, and topical methods. Additionally, the invention outlines methods for enhancing radiotherapy cancer treatment, particularly for astrocytomas, by administering a radiosensitizer composition alongside radiotherapy.
Another significant patent involves electroactive materials, specifically novel polymers containing 6,6,6-tricyclic moieties pendant from the polymer backbone. These polymers are easily synthesized, soluble in various solvents, and exhibit greater stability than traditional conductive polymers. A preferred tricyclic used in this invention is phenothiazine, which enhances the properties of the conductive polymers.
Career Highlights
Throughout his career, Robert Zand has worked with esteemed organizations such as Aisin Seiki Kabushiki Kaisha and the University of Michigan. His experiences in these institutions have contributed to his development as an inventor and researcher.
Collaborations
Zand has collaborated with notable colleagues, including Shinji Nezu and Selim Kusefoglu. These partnerships have likely enriched his work and expanded the impact of his inventions.
Conclusion
Robert Zand's contributions to the fields of radiosensitizers and electroactive materials highlight his innovative approach to solving complex problems. His patents reflect a commitment to advancing technology and improving cancer treatment methodologies.